Multicenter, prospective and open clinical study for rapamycin in the treatment of autoimmune hemolytic anemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023476

Enrollment

Unknown

Registered

2019-05-30

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune

Interventions

1:glucocorticoid

2:glucocorticoid & Ciclosporin

3:glucocorticoid & rapamycin

4:rapamycin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diganosed AIHA patients according to Criteria of diagnosis and curative effect of haematopathy and Chinese expert consensus on the diagnosis and treatment of autoimmune hemolytic anemia (2017). 2. Aged=16 years, male and female; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women; 2. Obvious abnormality of liver and kidney function (BUN, ScR, ALT and AST were more than 2.5 times of the normal upper limit); 3. Active viral hepatitis; 4. Severe infection; 5. With lesion of heart, brain and kidney etc..

Design outcomes

Primary

Measure	Time frame
Hemolysis;	—

Countries

China

Contacts

Public ContactShao Zonghong

Tianjin Medical University General Hospital

shaozonghong@sina.com+86 13802036467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026